Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer

Eleonora Farina; Jenny Capuccini; Gabriella Macchia; Luciana Caravatta; Nam P. Nguyen; Silvia Cammelli; Andrea Farioli; Giuseppe Zanirato Rambaldi; Savino Cilla; Tigeneh Wondemagegnhu; A.F.M. Kamal Uddin; Mostafà Aziz Sumon; Domenico Genovesi; Milly Buwenge; Francesco Cellini; Vincenzo Valentini; Francesco Deodato; Alessio G. Morganti

doi:10.21873/anticanres.12491

Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer

Eleonora Farina, Jenny Capuccini, Gabriella Macchia, Luciana Caravatta, Nam P. Nguyen, Silvia Cammelli, Andrea Farioli, Giuseppe Zanirato Rambaldi, Savino Cilla, Tigeneh Wondemagegnhu, A.F.M. Kamal Uddin, Mostafà Aziz Sumon, Domenico Genovesi, Milly Buwenge, Francesco Cellini, Vincenzo Valentini, Francesco Deodato, Alessio G. Morganti

Risultato della ricerca: Contributo in rivista › Articolo in rivista

6 Citazioni (Scopus)

Abstract

Aim: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. Patients and Methods: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. Results: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7%, with a median duration of palliation of 3 months. Conclusion: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies.

Lingua originale	English
pagine (da-a)	2409-2414
Numero di pagine	6
Rivista	Anticancer Research
Volume	38
DOI	https://doi.org/10.21873/anticanres.12491
Stato di pubblicazione	Pubblicato - 2018

Keywords

Adult
Aged
Aged, 80 and over
Carcinoma, Squamous Cell
Dose Fractionation, Radiation
Female
Head
Head and Neck Neoplasms
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neck cancer
Pain
Palliative Care
Palliative care
Quality of Life
Quality of life
Radiotherapy
Radiotherapy Dosage
Time Factors

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.21873/anticanres.12491

Altri file e collegamenti

Cita questo

Farina, E., Capuccini, J., Macchia, G., Caravatta, L., Nguyen, N. P., Cammelli, S., Farioli, A., Rambaldi, G. Z., Cilla, S., Wondemagegnhu, T., Uddin, A. F. M. K., Sumon, M. A., Genovesi, D., Buwenge, M., Cellini, F., Valentini, V., Deodato, F., & Morganti, A. G. (2018). Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer. Anticancer Research, 38, 2409-2414. https://doi.org/10.21873/anticanres.12491

@article{3729774e15154dc9b2898d8f254a5e76,

title = "Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer",

abstract = "Aim: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. Patients and Methods: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. Results: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7%, with a median duration of palliation of 3 months. Conclusion: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies.",

keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Dose Fractionation, Radiation, Female, Head, Head and Neck Neoplasms, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neck cancer, Pain, Palliative Care, Palliative care, Quality of Life, Quality of life, Radiotherapy, Radiotherapy Dosage, Time Factors, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Dose Fractionation, Radiation, Female, Head, Head and Neck Neoplasms, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neck cancer, Pain, Palliative Care, Palliative care, Quality of Life, Quality of life, Radiotherapy, Radiotherapy Dosage, Time Factors",

author = "Eleonora Farina and Jenny Capuccini and Gabriella Macchia and Luciana Caravatta and Nguyen, {Nam P.} and Silvia Cammelli and Andrea Farioli and Rambaldi, {Giuseppe Zanirato} and Savino Cilla and Tigeneh Wondemagegnhu and Uddin, {A.F.M. Kamal} and Sumon, {Mostaf{\`a} Aziz} and Domenico Genovesi and Milly Buwenge and Francesco Cellini and Vincenzo Valentini and Francesco Deodato and Morganti, {Alessio G.}",

year = "2018",

doi = "10.21873/anticanres.12491",

language = "English",

volume = "38",

pages = "2409--2414",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research:John G Delinassios, 1st Km Kapandritiou-Kalamou Road, Kapandriti Attiki 19014 Greece:011 30 2 2950 53389, 011 30 2950 52945, EMAIL: journals@iiar-anticancer.org, INTERNET: http://www.iiar-anticancer.org, Fax: 011 30 2 2950 53389, 011 30 2 2950 52945",

}

Farina, E, Capuccini, J, Macchia, G, Caravatta, L, Nguyen, NP, Cammelli, S, Farioli, A, Rambaldi, GZ, Cilla, S, Wondemagegnhu, T, Uddin, AFMK, Sumon, MA, Genovesi, D, Buwenge, M, Cellini, F , Valentini, V , Deodato, F & Morganti, AG 2018, 'Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer', Anticancer Research, vol. 38, pagg. 2409-2414. https://doi.org/10.21873/anticanres.12491

TY - JOUR

T1 - Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer

AU - Farina, Eleonora

AU - Capuccini, Jenny

AU - Macchia, Gabriella

AU - Caravatta, Luciana

AU - Nguyen, Nam P.

AU - Cammelli, Silvia

AU - Farioli, Andrea

AU - Rambaldi, Giuseppe Zanirato

AU - Cilla, Savino

AU - Wondemagegnhu, Tigeneh

AU - Uddin, A.F.M. Kamal

AU - Sumon, Mostafà Aziz

AU - Genovesi, Domenico

AU - Buwenge, Milly

AU - Cellini, Francesco

AU - Valentini, Vincenzo

AU - Deodato, Francesco

AU - Morganti, Alessio G.

PY - 2018

Y1 - 2018

N2 - Aim: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. Patients and Methods: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. Results: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7%, with a median duration of palliation of 3 months. Conclusion: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies.

AB - Aim: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. Patients and Methods: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. Results: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7%, with a median duration of palliation of 3 months. Conclusion: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Squamous Cell

KW - Dose Fractionation, Radiation

KW - Female

KW - Head

KW - Head and Neck Neoplasms

KW - Humans

KW - Male

KW - Maximum Tolerated Dose

KW - Middle Aged

KW - Neck cancer

KW - Pain

KW - Palliative Care

KW - Palliative care

KW - Quality of Life

KW - Quality of life

KW - Radiotherapy

KW - Radiotherapy Dosage

KW - Time Factors

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Squamous Cell

KW - Dose Fractionation, Radiation

KW - Female

KW - Head

KW - Head and Neck Neoplasms

KW - Humans

KW - Male

KW - Maximum Tolerated Dose

KW - Middle Aged

KW - Neck cancer

KW - Pain

KW - Palliative Care

KW - Palliative care

KW - Quality of Life

KW - Quality of life

KW - Radiotherapy

KW - Radiotherapy Dosage

KW - Time Factors

UR - http://hdl.handle.net/10807/149074

UR - http://ar.iiarjournals.org/content/38/4/2409.full.pdf+html

U2 - 10.21873/anticanres.12491

DO - 10.21873/anticanres.12491

M3 - Article

SN - 0250-7005

VL - 38

SP - 2409

EP - 2414

JO - Anticancer Research

JF - Anticancer Research

ER -

Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo